Drug intelligence / Profile preview

VYR-2020 (Vyripharm Biopharmaceuticals)

Development stage: Preclinical
Lead developer: Vyripharm Biopharmaceuticals
Modality: Small Molecules

Overview

VYR-2020 is a preclinical antiviral small molecule developed by Vyripharm Biopharmaceuticals for the treatment and diagnosis of viral infections, specifically targeting coronaviruses such as SARS-CoV-2 (COVID-19), SARS-CoV, and MERS-CoV. It is designed as part of a multi-component theranostic platform that integrates nuclear medicine imaging with antiviral therapy. The platform often utilizes VYR-2020 in conjunction with a CB1 antagonist (such as VYR-206 or a related analogue) to monitor disease progression and therapeutic efficacy through a radiotherapeutic regimen. Vyripharm partnered with Regis Technologies for cGMP manufacturing to facilitate the transition from preclinical studies to first-in-human clinical trials.

Other names: Anti-viral therapeutic formulationVyripharm coronavirus antiviral

Beyond the preview

Go deeper on VYR-2020 (Vyripharm Biopharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-2020 (Vyripharm Biopharmaceuticals).

Explore the full profile